Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

Cxcl8 Expands Hematopoietic Stem and Progenitor Cells and Alters Their Interaction with the Endothelial Niche

Donn L Calkins, BS, Jami L Shaffer, B.S., Emily M Teets, B.S., Alex M Belardo, Serine Avagyan, MD PhD, Leonard I Zon, MD, Bradley W Blaser, MD PhD

Blood (2019) 134 (Supplement_1): 527.

https://doi.org/10.1182/blood-2019-126151

Published: 2019

Journal Articles

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Jeffrey E. Lancet, MD, David A. Rizzieri, MD, Gary J. Schiller, MD, Scott R. Solomon, MD, Laura F. Newell, MD, Harry P. Erba, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1313.

https://doi.org/10.1182/blood-2019-124383

Published: 2019

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Tara L. Lin, MD, Daniel H. Ryan, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1316.

https://doi.org/10.1182/blood-2019-124552

Published: 2019

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

Fabio Guolo, MD, Paola Minetto, MD, Luana Fianchi, MD, Michela Rondoni, MD, Giulia Daghia, MD, Stefano D'Ardia, MD, Monica Morselli, MD, Crescenza Pasciolla, MD, Francesca Pavesi, MD, Barbara MD Scappini, Francesco Lanza, MD, Marco Gobbi, MD, Livio Pagano, MD, Felicetto Ferrara, MD, Roberto Massimo Lemoli, MD

Blood (2019) 134 (Supplement_1): 1363.

https://doi.org/10.1182/blood-2019-131329

Published: 2019

Journal Articles

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Swaminathan P. Iyer, MD, Brad M. Haverkos, MDMPH,MS, Jasmine Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 2831.

https://doi.org/10.1182/blood-2019-123954

Published: 2019

Journal Articles

Bovine Heparin Demonstrates the Same Interaction with HIT Antibodies As Porcine Heparin

Jeanine Walenga, PhD, Walter Jeske, PhD, Sabrina Bertini, Giulia Risi, Michelle Sung, BS, Ambar Farooqui, Cassie Bacher, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Bruce Lewis, Mamdouh Bakhos, MD

Blood (2019) 134 (Supplement_1): 2351.

https://doi.org/10.1182/blood-2019-127304

Published: 2019

Journal Articles

Anti-Tumor Effect of the EZH1/2 Dual Inhibitor Valemetostat Against Diffuse Large B-Cell Lymphoma Via Modulation of B-Cell Receptor Signaling and c-Myc Signaling Pathways

Yasuhiro Hama, PhD, Toshihiro Banjo, PhD, Daisuke Honma, PhD, Yoshimi Takata, Emi Nosaka, Machiko Shiroishi, Kenji Watanabe, Yuka Yamamoto, Tsuyoshi Hirata, Rika Nakano, Koichiro Inaki, PhD, Hiroki Goto, PhD, Yusuke Totoki, PhD, Miki Kataoka, Kyungtaek Lim, PhD, Chisa Wada, Eiji Kumazawa, PhD, Shinji Tsutsumi, PhD

Blood (2019) 134 (Supplement_1): 4642.

https://doi.org/10.1182/blood-2019-125436

Published: 2019

Journal Articles

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Artavazd Arumov, BSc, Piumi Y. Liyanage, BS, Asaad Trabolsi, MD, Lingxiao Li, PhD, Evan R. Roberts, BS, Daniel Bilbao, PhD, Roger M. LeBlanc, PhD, Jonathan H. Schatz, MD

Blood (2019) 134 (Supplement_1): 4061.

https://doi.org/10.1182/blood-2019-122599

Published: 2019

Journal Articles

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Jonathan E. Kolitz, MD, Daniel H. Ryan, MD, Laura F. Newell, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Gary J. Schiller, MD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3856.

https://doi.org/10.1182/blood-2019-124553

Published: 2019

Journal Articles

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Ellen K. Ritchie, MD, Sumaiya K. Miah, BA, Sangmin Lee, MD, Tania Curcio, Pinkal Desai, MDMPH, Jeffrey Ball, MD, Michael B. Samuel, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 3858.

https://doi.org/10.1182/blood-2019-130263

Published: 2019

Journal Articles

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Rafael Heinz Montoya, Naval G. Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2556.

https://doi.org/10.1182/blood-2019-126950

Published: 2019

Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD

Blood (2019) 134 (Supplement_1): 2213.

https://doi.org/10.1182/blood-2019-127075

Published: 2019

Journal Articles

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Anuja Khan, PhD, Krisjela Shishko, BS, Sam Arcidiacono, BS, Khanh Bui, BS, Genmin Lu, Pamela B. Conley, PhD, Anne Winkler, MD

Blood (2019) 134 (Supplement_1): 1153.

https://doi.org/10.1182/blood-2019-126254

Published: 2019

Journal Articles

Phospholipid-Independent Activity of Fviiia Mimetic Bispecific Antibodies in Plasma

Maria M Aleman, PhD, Siddharth Jindal, MS, Nina Leksa, PhD, Robert Peters, PhD, Joe Salas, PhD

Blood (2018) 132 (Supplement 1): 2461.

https://doi.org/10.1182/blood-2018-99-119226

Published: 2018

Journal Articles

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

Michael J. Absalon, MD PhD, Erin H. Breese, MD PhD, Lynn Lee, MD, Maureen M O'Brien, MD MS, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, MD, Qi An, Jennifer Mangino, MD, Joel Kaplan, DO, Robin Norris, MD, John Peter Perentesis, MD

Blood (2018) 132 (Supplement 1): 336.

https://doi.org/10.1182/blood-2018-99-119618

Published: 2018

Journal Articles

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

Qi Wang, PhD, Sarah F. Cook, Scott A. Van Wart, Donald E. Mager, Stefan Faderl, MD

Blood (2018) 132 (Supplement 1): 4037.

https://doi.org/10.1182/blood-2018-99-111918

Published: 2018

Journal Articles

Global Gene Expression Analysis Reveals Genotoxic Effect of Nrf2 Pharmacological Inhibitor Brusatol in Myeloid Leukemia Cells- a Promising Novel Anticancer Agent

Raveen Stephen Stallon Illangeswaran, MSc, Sreeja Karathedath, PhD, Bharathi M Rajamani, Poonkuzhali Balasubramanian, MSc

Blood (2018) 132 (Supplement 1): 5150.

https://doi.org/10.1182/blood-2018-99-117829

Published: 2018

Journal Articles

DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation

Blood (2018) 132 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2018-99-113379

Published: 2018

Journal Articles

Enhanced Renal Clearance of Heme Triggers Acute Kidney Injury in Sickle Cell Disease

Samit Ghosh, PhD, Vivian Paintsil, MD, Rimi Hazra, PhD, Oluowaseun O. Orikogbo, Bethany Flage, Ezekiel Bonwin Ackah, Ellis Owusu-Dabo, PhD, Solomon Fiifi Ofori-Acquah, PhD

Blood (2017) 130 (Supplement 1): 441.

https://doi.org/10.1182/blood.V130.Suppl_1.441.441

Published: 2017

NARROW

Cxcl8 Expands Hematopoietic Stem and Progenitor Cells and Alters Their Interaction with the Endothelial Niche

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Bovine Heparin Demonstrates the Same Interaction with HIT Antibodies As Porcine Heparin

Anti-Tumor Effect of the EZH1/2 Dual Inhibitor Valemetostat Against Diffuse Large B-Cell Lymphoma Via Modulation of B-Cell Receptor Signaling and c-Myc Signaling Pathways

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Phospholipid-Independent Activity of Fviiia Mimetic Bispecific Antibodies in Plasma

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

Global Gene Expression Analysis Reveals Genotoxic Effect of Nrf2 Pharmacological Inhibitor Brusatol in Myeloid Leukemia Cells- a Promising Novel Anticancer Agent

DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation

Enhanced Renal Clearance of Heme Triggers Acute Kidney Injury in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only